FPAS
TAK icon

Focus Partners Advisor Solutions’s Takeda Pharmaceutical TAK Stock Holding History

Focus Partners Advisor Solutions’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186K Buy
+10,049
New +$176K ﹤0.01% 1167
2025
Q3 		– Sell
-10,225
Closed -$158K – 1280
2025
Q2 		$158K Buy
+10,225
New +$151K ﹤0.01% 1041

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Focus Partners Advisor Solutions's TAK Position: Q1 2026 in Review

Focus Partners Advisor Solutions opened a new position in Takeda Pharmaceutical (TAK) in Q1 2026: 10,049 shares worth $186K. The stake represents ﹤0.01% of the portfolio and ranks #1167 among its holdings. This is a return to the name: Focus Partners Advisor Solutions previously reported a position in TAK as recently as Q2 2025.

Focus Partners Advisor Solutions first reported a position in TAK in Q2 2025 and has held it in 2 quarters since. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Focus Partners Advisor Solutions held 10,049 shares of Takeda Pharmaceutical worth $186K as of Q1 2026.
  • Takeda Pharmaceutical was a new Focus Partners Advisor Solutions position in Q1 2026.
  • Takeda Pharmaceutical made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1167 holding.
  • Focus Partners Advisor Solutions first reported a position in Takeda Pharmaceutical in Q2 2025 and has held it in 2 quarters since.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.